Artificial intelligence (AI) company Anthropic has established a biology research laboratory in the San Francisco Bay Area as it expands beyond computer-based analysis and into physical experimentation.
For clinical laboratories and pathology groups, Anthropic’s investment suggests that AI companies increasingly may become more than software vendors. They could become research partners—or competitors—for scientists, laboratory data, automation expertise, and pharmaceutical relationships.
Eric Kauderer-Abrams, Anthropic’s head of life sciences, confirmed that the developer of the Claude AI models is performing laboratory work internally and through external partners, Engadget reported.
“We believe that to do biology, the final test is still and will be for a while in real lab work,” he said.
Anthropic has not disclosed the specific experiments underway. The laboratory also was not created exclusively for drug discovery, Engadget noted.
However, the company is exploring whether Claude can direct robotic equipment to conduct scientific experiments. Kauderer-Abrams described the use of AI to automate laboratory work as being in its early stages and emphasized the continuing need for human oversight.
Anthropic has not conducted clinical trials. Its current work remains focused on biological research rather than clinical laboratory testing or patient diagnosis.
Nevertheless, the move is notable for clinical laboratories because it places a major AI developer directly inside a working laboratory. Anthropic can now connect AI-generated hypotheses with automated experiments and the laboratory data those experiments produce.
Anthropic expands life sciences strategy
The laboratory is part of a broader life sciences expansion at Anthropic.
Earlier in 2026, the company acquired AI biotechnology startup Coefficient Bio in a stock transaction reportedly valued at approximately $400 million. Coefficient Bio’s team included former Genentech computational biology researchers, R&D World reported.
Anthropic also has formed research partnerships with the Allen Institute and Howard Hughes Medical Institute. According to an Anthropic announcement, the collaborations will develop specialized AI agents that can help scientists plan, perform, and interpret experiments.
The company recently introduced a Life Sciences Verification Program that gives approved pharmaceutical companies, biotechnology firms, and academic laboratories access to Claude models with fewer restrictions on legitimate biological research. Applicants must undergo reviews of their credentials, security measures, and ethical oversight.
The initiative also offers a glimpse of laboratory systems that may eventually help design experiments, operate instruments, analyze results, and determine which experiment should be performed next.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
